

Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid

DANIEL GLENN KINDELL¹, RICK WAYNE KECK¹ and JERZY JANKUN¹⁻³

¹Urology Research Center, Department of Urology, University of Toledo, Health Science Campus, Toledo, OH 43614, USA;

²Protein Research Chair, Department of Biochemistry, College of Sciences, King Saud University,

Riyadh 11451, Kingdom of Saudi Arabia; ³Department of Clinical Nutrition,

Medical University of Gdańsk, Gdańsk, Pomerania 80-211, Poland

Received August 20, 2014; Accepted November 17, 2014

DOI: 10.3892/etm.2015.2399

Abstract. Plasminogen activator inhibitor (PAI)-1 is a serpin glycoprotein that can stabilize blood clots by inhibiting fibrinolysis. However, wild-type PAI-1 has the disadvantage of a short half-life of ~2 h. A very long half-life (VLHL) PAI-1 mutant was developed previously with an active-form half-life of >700 h, making it a possible candidate for use in hemorrhagic therapy. Current treatments for mitigating hemorrhage, other than inducers of blood clotting, are limited to lysine analog antifibrinolytics, including 6-aminocaproic acid and tranexamic acid. VLHL PAI-1 has been previously demonstrated to limit bleeding; however, the efficacy of this protein compared with lysine analog antifibrinolytics has not been investigated. The aim of the current study was to compare the clot stabilizing properties of the novel antifibrinolytic VLHL PAI-1 with those of 6-aminocaproic acid in reference plasma. Using thromboelastographic analysis, VLHL PAI-1 exhibited an IC₅₀ (half maximal inhibitory concentration) of 8.8x10⁻⁸ mol/l, while 6-aminocaproic acid showed an IC₅₀ of 1.6x10⁻⁴ mol/l. However, at doses of >9.0x10⁻⁷ mol/l, VLHL PAI-1 exhibited a delay in the onset of clot formation, which may be attributed to thrombin inhibition by excess PAI-1. The inhibition of tissue plasminogen activator by VLHL PAI-1 demonstrated improved efficacy over 6-aminocaproic acid in mitigating hemorrhage. In addition, patients with a PAI-1 deficiency, which causes blood clots to lyse rapidly resulting in profuse bleeding, may benefit from the application of VLHL PAI-1 as an antihemorrhagic therapy.

Introduction

Coagulation, the formation of a clot, is an essential process in the maintenance of homeostasis under normal conditions and during traumatic events. Numerous agents are used to initiate clotting and prevent uncontrolled bleeding. However, only a few agents, with limited efficacy, are used in clinical practice to protect formed clots against premature lysis (1,2). The crosslinked polymer, fibrin, is dissolved into fibrin degradation products by plasmin. Thus, preventing the activation of plasmin is a potential target for antihemorrhage therapy. Plasmin, the primary fibrinolytic protease responsible for fibrin solvation, is formed by proteolytic cleavage of the zymogen plasminogen by tissue plasminogen activator (tPA) or urokinase plasminogen activator (uPA) (3-6). Vascular endothelial cells synthesize tPA, and tPA-mediated plasminogen activation is accelerated in the presence of fibrin (5,6).

An appropriate level of plasminogen activation is maintained through the competing activity of plasminogen activators and plasminogen activator inhibitors (PAIs). The most relevant PAI in clot formation is PAI-1 (7), which is the quickest acting and most physiologically specific inhibitor of tPA (5,8). The three conformational states of PAI-1 are latent (inactive), active and reactive-center-cleaved (plasminogen-activator complexed) (9). The active form of PAI-1 is rapidly converted (half-life, 1-2 h) into the latent form at physiological temperatures and pH (6,7,10). This relatively short half-life makes it difficult to use PAI-1 therapeutically as a clot protector. However, a previous study described a novel, genetically-engineered, antifibrinolytic PAI-1 with a significantly longer half-life (>700 h) compared with the wild-type (11).

The aim of the present study was to compare the antifibrinolytic activity of this very long half-life PAI-1 (VLHL PAI-1) with 6-aminocaproic acid (also known as ε-aminocaproic acid or Amicar) in the presence of tPA by establishing dose-response curves and determining the IC₅₀ (half maximal inhibitory concentration) using thromboelastography (TEG).

Correspondence to: Professor Jerzy Jankun, Urology Research Center, Department of Urology, University of Toledo, Health Science Campus, 3,000 Arlington Avenue, Toledo, OH 43614, USA
E-mail: jerzy.jankun@utoledo.edu

Key words: plasminogen activator inhibitor-1, 6-aminocaproic acid, thromboelastography, blood clotting

Table I. Selected thrombelastography parameters for the control-, VLHL PAI-1- and 6AC-treated reference plasma.

Reagent (μg)	R (min)	K (min)	A ($^{\circ}$)	MA (mm)	LY ₃₀ (%)	G (kdyn/cm ²)
Control						
Reference	8.57 \pm 0.45	2.04 \pm 0.62	63.7 \pm 5.6	26.2 \pm 2.2	0.0 \pm 0.0	1.77 \pm 0.19
tPA-treated	8.09 \pm 0.71	2.30 \pm 0.55	63.9 \pm 4.7	19.3 \pm 2.5	87.5 \pm 7.5	1.21 \pm 0.19
VLHL PAI-1						
25.0	18.27 \pm 4.75	5.80 \pm 1.80	35.6 \pm 7.4	30.2 \pm 1.5	0.0 \pm 0.0	2.17 \pm 0.11
12.5	23.75 \pm 0.70	8.90 \pm 5.37	32.1 \pm 13.2	26.9 \pm 0.6	0.0 \pm 0.0	1.85 \pm 0.07
6.25	9.10 \pm 0.45	2.67 \pm 1.55	62.0 \pm 2.8	26.4 \pm 0.6	0.0 \pm 0.0	1.82 \pm 0.35
3.12	8.70 \pm 0.28	6.05 \pm 4.87	65.0 \pm 13.1	21.1 \pm 1.2	0.0 \pm 0.0	1.35 \pm 0.07
0.78	7.05 \pm 0.77	2.30 \pm 1.55	63.3 \pm 7.1	24.8 \pm 4.5	32.9 \pm 1.3	1.70 \pm 0.42
0.39	8.00 \pm 0.98	1.55 \pm 0.49	71.2 \pm 2.4	22.9 \pm 2.1	85.0 \pm 2.3	1.50 \pm 0.14
0.19	7.25 \pm 0.77	N/A	62.4 \pm 4.8	15.6 \pm 3.6	91.8 \pm 0.5	0.90 \pm 0.28
6AC						
36.0	8.20 \pm 0.00	2.10 \pm 0.42	63.3 \pm 8.4	22.8 \pm 0.2	0.0 \pm 0.0	1.50 \pm 0.00
27.0	8.85 \pm 0.91	5.10 \pm 2.68	54.3 \pm 2.9	21.1 \pm 1.4	0.1 \pm 0.1	1.35 \pm 0.07
18.0	8.20 \pm 0.40	2.10 \pm 0.30	67.0 \pm 2.8	23.0 \pm 2.7	2.4 \pm 2.3	1.50 \pm 0.26
9.0	8.00 \pm 0.70	1.60 \pm 0.28	68.3 \pm 3.6	24.0 \pm 0.6	35.7 \pm 12.7	1.55 \pm 0.07
4.5	8.85 \pm 1.20	1.65 \pm 0.07	67.3 \pm 1.6	24.2 \pm 1.1	48.3 \pm 1.1	1.60 \pm 0.14
1.12	8.00 \pm 0.00	1.80 \pm 0.00	70.2 \pm 0.0	21.8 \pm 0.0	80.7 \pm 0.0	1.40 \pm 0.00
0.75	8.55 \pm 0.07	2.25 \pm 0.07	62.9 \pm 2.4	21.4 \pm 0.6	87.1 \pm 0.3	1.35 \pm 0.07

Values are expressed as the mean \pm standard deviation. R, reaction time; K, time from reaction until a 20-mm clot formed; A, degree indicating the speed of clot formation; MA, maximum amplitude (maximum dynamic properties of platelet-fibrin interaction and contribution of fibrin to clot strength); G, clot strength (derived from MA); LY₃₀, clot lysis 30 min after MA [detailed descriptions can be found in previous studies (14,17,32)]; VLHL PAI-1, very long half life plasminogen activator inhibitor-1; 6AC, 6-aminocaproic acid.

Materials and methods

Clot-protecting activity assay. A clot-protecting activity assay was performed using a TEG[®] 5000 Thrombelastograph[®] (Haemonetics Corporation, Braintree, MA, USA). The thrombelastograph measured coagulation with a pin attached to a torsion wire suspended in a cup holding a plasma sample. The TEG[®] was calibrated with plasma controls Level I (reading of TEG parameters within: R, 0-4 min; Angle, 75-87 $^{\circ}$; MA, 42-63 mm; K, 0-2 min) and II (reading of TEG parameters within: R, 1-5 min; Angle, 60-80 $^{\circ}$; MA, 26-41 mm; K, 0-6 min) (Haemoscope Corporation, Neils, IL, USA). Reference plasma (Coagulation Specialty Assayed Reference Plasma; Helena Laboratories Corporation, Beaumont, TX, USA) was reconstituted in 1 ml distilled water and mixed with 20 μl kaolin (Haemonetics Corporation). In trials where tPA was utilized, 20 μl tPA (2 mg/ml; Molecular Innovations, Novi, MI, USA) was added directly to the plasma. Next, 320 μl plasma/kaolin solution was added to the TEG[®] cup containing 20 μl calcium chloride (0.2 M).

Trials. Each trial consisted of two samples running simultaneously, containing the same plasma/kaolin solution. The control TEG[®] cup received 10 μl distilled water and the experimental TEG[®] cup received the appropriate combination of VLHL PAI-1, 6-aminocaproic acid (Sigma-Aldrich, St. Louis, MI, USA) and distilled water. The 6-aminocaproic acid was reconstituted with distilled water. Expression and

purification of VLHL PAI-1 was conducted as described in a previous study (6). Serial dilutions of VLHL PAI-1 were performed with saline (0.15 M) and each trial ran for 45 min at 37 $^{\circ}\text{C}$.

Statistical analysis. Statistical analysis was performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA), and differences between the groups were analyzed by two-way analysis of variance. The data were presented as the mean \pm standard deviation, and $P < 0.05$ was considered to indicate a statistically significant difference. Graph visualization was performed using Origin 8 software (OriginLab, Northampton, MA, USA).

Results

Clotting parameters for the reference and tPA-treated plasma. Selected clotting parameters for the control and various doses of 6-aminocaproic acid and VLHL PAI-1 are shown in Table I and Figs. 1 and 2. Control samples consisted of reference and tPA-treated plasma, with tPA included to mimic clot lysis. Reference and tPA-treated plasma exhibited similar average control values, with the exception of a lower clot strength (G), maximum amplitude (MA) and rate of clot lysis after 30 min (LY₃₀) in the tPA-treated plasma due to tPA-induced clot lysis, which is consistent with previous studies (12-16). The MA was lower, as reference plasma lacks platelets that strengthen the blood clot (3,17-19). There are no normal values of TEG




Figure 1. Effects of various concentrations of VLHL PAI-1 (circles) and 6AC (squares) on the R, G and LY₃₀ values. IC₅₀ values (half maximal inhibitory concentrations) were calculated from the linear fit of four points for VLHL PAI-1 (IC₅₀=8.8x10⁻⁸ mol/l) and the linear fit of five points for 6AC (IC₅₀=1.6x10⁻⁴ mol/l). R, reaction time; G, strength of clot; LY₃₀, clot lysis 30 min after the maximum amplitude; 6AC, 6-aminocaproic acid; VLHL PAI-1, very long half life plasminogen activator inhibitor-1.




Figure 2. (A) Reference plasma clotted with kaolin and calcium alone (solid line) and with kaolin, calcium and tissue plasminogen activator (tPA; dotted line). Dotted line shows that the clot was quickly dissolved by tPA-activated plasmin. (B) Reference plasma clotted with kaolin, calcium, tPA and very long half life plasminogen activator inhibitor-1 (VLHL PAI-1) and with kaolin, calcium, tPA and a high concentration of VLHL PAI-1 (dotted line). Solid line shows that the addition of VLHL PAI-1 protected the clot from lysis, while the dotted line shows that increased concentrations of VLHL PAI-1 protected the clot from lysis, but delayed clot formation (reduced time from reaction until a 20-mm clot formed) and reduced the angle of clot formation, indicating decreased fibrin cross-linking (reduced A). A, angle is the rate of clot development indicated by fibrinogen and fibrin cross-linking.

parameters for reference plasma in the literature. However, normal blood samples are considered to have a reaction time (R) of 2-8 min, a 2-4-min period between the reaction onset and the formation of a 20-mm clot, an MA of 51-69 mm and a LY₃₀ value of 0-8% (12).

6-aminocaproic acid treatment decreases the incidence rate of clot lysis after 30 min. Doses of 6-aminocaproic acid that were ≥18 μg generated LY₃₀ values of ≤5%, indicating that the formed fibrin clot was almost entirely intact. Serial dilutions of ≤9 μg yielded significantly different (P<0.01) LY₃₀ values, ranging

between 26.7 and 87.4%, as compared with the controls (Fig. 1). The IC_{50} of 6-aminocaproic acid was $6.5 \mu\text{g}$ or $1.6 \times 10^{-4} \text{ mol/l}$ when expressed as a concentration. No dosage of 6-aminocaproic acid produced a delay in clot formation (Fig. 1). The maximum G achieved by 6-aminocaproic acid was 1.8 kdyn/cm^2 .

VLHL PAI-1 treatment decreases incidence rate of clot lysis after 30 min. At doses of $\geq 3.125 \mu\text{g}$ VLHL PAI-1, tPA action was completely inhibited, generating LY_{30} values of 0%. Doses of $\leq 0.78 \mu\text{g}$ generated statistically significant differences ($P < 0.01$) in LY_{30} values, which ranged between 32.1 and 92.2%, as compared with the controls. The IC_{50} of VLHL PAI-1 was $0.68 \mu\text{g}$ or $8.8 \times 10^{-8} \text{ mol/l}$ when expressed as a concentration (Fig. 1). In addition, VLHL PAI-1 doses of $\geq 12.5 \mu\text{g}$ produced a statistically significant ($P < 0.01$) increase in R, as compared with the controls (Fig. 2). VLHL PAI-1 achieved a maximum G of 2.3 kdyn/cm^2 .

Discussion

There are three conformational states of PAI-1, including latent (inactive), active and reactive-center-cleaved (plasminogen-activator-complex) (9,10). The active form of PAI-1 is rapidly converted (half-life, 1-2 h) into the latent form at a physiological temperature and pH (7,9,10,20). The reactive center loop of PAI-1, which contains the active site, is connected to β -sheet C at the C-terminal and β -sheet A at the N terminal (9). In the latent form, the reactive center loop is inserted into β -sheet A (central β -sheet), thereby eliminating the possibility of proteinase interaction with the reactive peptide bond (P1-P1') of tPA or uPA, and PAI-1 becomes inactive (7,9,10). Thus, only active PAI-1 can be used as a clot protector. We previously developed a VLHL PAI-1 mutant that remained active for $>700 \text{ h}$, and despite the two cysteine mutations, the VLHL PAI-1 structure was found to be almost identical to wild-type PAI-1 (10,11,21,22). The long half-life of VLHL PAI-1 has enabled this protein to become a potential therapeutic agent for the mitigation of bleeding.

None of the current antifibrinolytics, including aprotinin, 6-aminocaproic acid and tranexamic acid (TXA), are without side effects, warranting the development of new hemostatic agents (14). TXA has been shown to have a statistical association with seizure induction, possibly due to cerebral ischemia caused by a decrease in regional or global cerebral blood flow (20). Aprotinin functions via the same mechanism as PAI-1, while lysine analogs, such as 6-aminocaproic acid and TXA, block the lysine-binding sites on plasminogen, thereby preventing the activation of plasmin and fibrin clot-degradation (19). The USA Food and Drug Administration has removed aprotinin, a bovine product, from the market due to statistical associations with renal failure, cerebrovascular events and mortality, without significantly stronger antifibrinolytic effects over other medications within the class (23-25). As a natural constituent of blood, VLHL PAI-1 may be free of side effects in addition to being an efficient antifibrinolytic agent.

Using a number of *in vitro*, *ex vivo* and *in vivo* models, previous studies have shown that VLHL PAI-1 is able to reduce clot lysis and bleeding in animal experiments (12-14,17). However, the efficacy of this protein had not been compared

with other antifibrinolytics. The present study showed that VLHL PAI-1 is a more effective blood clot-protector than 6-aminocaproic acid. Racanelli *et al* compared recombinant wild PAI-1 to 6-aminocaproic acid in a rabbit model and found that the molar ED_{50} (effective dose for 50% of population base) was 25,000 times higher for 6-aminocaproic acid than for PAI-1. It was also found that complete inhibition of blood loss was achieved with PAI-1, but the highest dose of 6-aminocaproic acid did not completely inhibit blood loss (26). This outcome supports the conclusions of the present study. However, the absence of platelets and associated platelet function in reference plasma makes the clot weaker. This lack of thrombocytes in the reference plasma may cause 6-aminocaproic acid to exhibit an ED_{50} value $\sim 2,000$ times higher than that of VLHL PAI-1.

Notably, an increase in R was observed in $\geq 12.5 \mu\text{g}$ VLHL PAI-1 ($9.0 \times 10^{-7} \text{ mol/l}$) cases. This phenomenon may be explained by the interaction of thrombin with PAI-1 and the simultaneous formation of cleaved PAI-1 and thrombin-PAI-1 complexes. The kinetics of this reaction are described by a suicide substrate model with a branched reaction that ends in the inhibitor/enzyme complex, the cleaved inhibitor and free enzyme. Due to the branched pathway, it was proposed that 3 mol PAI-1 was required to completely inhibit 1 mol thrombin (27). Since thrombin, a serine protease, converts soluble fibrinogen into insoluble strands of fibrin indirectly through factor XIII, inhibition of thrombin by excess PAI-1 increases the time required for clot formation.

VLHL PAI-1 may also be implemented as a treatment for PAI-1 deficiency. This condition is caused by a lack of PAI-1, an abnormality in the PAI-1 molecule itself, or defects in the secretory dynamics of PAI-1 in the blood (16,28-31). PAI-1 deficiency, a clinically rare bleeding disorder, is characterized by hyperfibrinolytic hemorrhage in the presence of normal thrombus formation (7,9). Patients experience multiple episodes of uncontrolled bleeding, and in severe cases, require blood product transfusions (16,28-31). The class of medications currently used to treat PAI-1 deficiency are antifibrinolytics, which function by inhibiting the conversion of plasminogen into plasmin (22). There are three primary antifibrinolytics utilized in the clinical treatment of the disease: Aprotinin, 6-aminocaproic acid and TXA, which are not always effective and may exhibit a number of side effects (26). Bleeding occurs due to the unopposed conversion of plasminogen to plasmin by the action of tPA and subsequent fibrinolytic activity. Infusion of VLHL PAI-1, structurally homologous to wild-type PAI-1, may provide prophylactic treatment for these patients and restore them to normal health (12-14,28,30).

In conclusion, the inhibition of tPA by VLHL PAI-1 demonstrates an improved efficacy over 6-aminocaproic acid in managing hemorrhagic events in the general patient population. However, concentrations of $>9.0 \times 10^{-7} \text{ mol/l}$ VLHL PAI-1 may delay the initiation and dynamics of clot formation. Therefore, in therapy, VLHL PAI-1 should be used in concentrations $<9.0 \times 10^{-7} \text{ mol/l}$.

Acknowledgements

This study was supported in part by grants from the Frank Stranahan Endowed Chair and Children's Miracle Network.

References

1. Antun AG, Gleason S, Arellano M, *et al*: Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. *Cancer* 119: 3784-3787, 2013.
2. Dhir A: Antifibrinolytics in cardiac surgery. *Ann Card Anaesth* 16: 117-125, 2013.
3. Jankun J and Skrzypczak-Jankun E: Plasminogen activator inhibitor with very long half-life (VLHL PAI-1) can reduce bleeding in PAI-1-deficient patients. *Cardiovasc Hematol Disord Drug Targets* 13: 144-150, 2013.
4. Mosesson MW: Fibrinogen and fibrin structure and functions. *J Thromb Haemost* 3: 1894-1904, 2005.
5. Rau JC, Beaulieu LM, Huntington JA and Church FC: Serpins in thrombosis, hemostasis and fibrinolysis. *J Thromb Haemost* 5 (Suppl 1): 102-115, 2007.
6. Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R and Estellés A: Fibrinolysis: the key to new pathogenetic mechanisms. *Curr Med Chem* 15: 923-929, 2008.
7. Dellas C and Loskutoff DJ: Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. *Thromb Haemost* 93: 631-640, 2005.
8. Cesarman-Maus G and Hajjar KA: Molecular mechanisms of fibrinolysis. *Br J Haematol* 129: 307-321, 2005.
9. Egelund R, Schousboe SL, Sottrup-Jensen L, Rodenburg KW and Andreasen PA: Type-1 plasminogen-activator inhibitor - conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. *Eur J Biochem* 248: 775-785, 1997.
10. Jankun J, Yang J, Zheng H, Han FQ, Al-Senaidy A and Skrzypczak-Jankun E: Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure. *Int J Mol Med* 29: 61-64, 2012.
11. Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH and Jankun J: A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. *Mol Cancer Ther* 2: 19-28, 2003.
12. Jankun J, Aleem AM, Selman SH, *et al*: Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. *Int J Mol Med* 20: 683-687, 2007.
13. Jankun J, Keck R, Selman SH and Skrzypczak-Jankun E: Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss. *Int J Mol Med* 26: 501-504, 2010.
14. Jankun J, Selman SH, Keck RW, Łysiak-Szydłowska W and Skrzypczak-Jankun E: Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model. *BJU Int* 105: 1469-1476, 2010.
15. Jankun J, Skotnicka M, Łysiak-Szydłowska W, Al-Senaidy A and Skrzypczak-Jankun E: Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea. *Int J Mol Med* 27: 525-529, 2011.
16. Jankun J and Skrzypczak-Jankun E: Yin and yang of the plasminogen activator inhibitor. *Pol Arch Med Wewn* 119: 410-417, 2009.
17. Jankun J, Aleem AM, Struniawski R, Łysiak-Szydłowska W, Selman SH and Skrzypczak-Jankun E: Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. *Pharmacol Rep* 61: 673-680, 2009.
18. Morimoto Y, Yoshioka A, Imai Y, Takahashi Y, Minowa H and Kirita T: Haemostatic management of intraoral bleeding in patients with congenital deficiency of alpha2-plasmin inhibitor or plasminogen activator inhibitor-1. *Haemophilia* 10: 669-674, 2004.
19. Schulman S: Pharmacologic tools to reduce bleeding in surgery. *Hematology Am Soc Hematol Educ Program* 2012: 517-521, 2012.
20. Makhija N, Sarupria A, Kumar Choudhary S, Das S, Lakshmy R and Kiran U: Comparison of epsilon aminocaproic acid and tranexamic acid in thoracic aortic surgery: clinical efficacy and safety. *J Cardiothorac Vasc Anesth* 27: 1201-1207, 2013.
21. Harrop SJ, Jankova L, Coles M, *et al*: The crystal structure of plasminogen activator inhibitor 2 at 2.0 Å resolution: implications for serpin function. *Structure* 7: 43-54, 1999.
22. Sharp AM, Stein PE, Pannu NS, *et al*: The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. *Structure* 7: 111-118, 1999.
23. Fergusson DA, Hébert PC, Mazer CD, *et al*; BART Investigators: A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. *N Engl J Med* 358: 2319-2331, 2008.
24. Howell N, Senanayake E, Freemantle N and Pagano D: Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. *J Thorac Cardiovasc Surg* 145: 234-240, 2013.
25. Iribarren JL, Jimenez JJ, Hernández D, *et al*: Postoperative bleeding in cardiac surgery: the role of tranexamic acid in patients homozygous for the 5G polymorphism of the plasminogen activator inhibitor-1 gene. *Anesthesiology* 108: 596-602, 2008.
26. Racanelli AL, Diemer MJ, Dobies AC, Dubin JR and Reilly TM: Comparison of recombinant plasminogen activator inhibitor-1 and epsilon amino caproic acid in a hemorrhagic rabbit model. *Thromb Haemost* 67: 692-696, 1992.
27. van Meijer M, Smilde A, Tans G, Nesheim ME, Pannekoek H and Horrevoets AJ: The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. *Blood* 90: 1874-1882, 1997.
28. Fay WP, Parker AC, Condrey LR and Shapiro AD: Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. *Blood* 90: 204-208, 1997.
29. Jankun J and Skrzypczak-Jankun E: Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1. *Exp Ther Med* 1: 575-577, 2010.
30. Mehta R and Shapiro AD: Plasminogen activator inhibitor type 1 deficiency. *Haemophilia* 14: 1255-1260, 2008.
31. Schleaf RR, Higgins DL, Pillemer E and Levitt LJ: Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. *J Clin Invest* 83: 1747-1752, 1989.
32. Genét GF, Ostrowski SR, Sørensen AM and Johansson PI: Detection of tPA-induced hyperfibrinolysis in whole blood by RapidTEG, KaolinTEG, and functional fibrinogenTEG in healthy individuals. *Clin Appl Thromb Hemost* 18: 638-644, 2012.